Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

In general, antidepressant drugs are regarded as too slow acting. Most patients who benefit from treatment require more than 2 weeks of therapy to respond to treatment. An efficacious and well-tolerated antidepressant drug with an earlier onset of effect would be of greater interest to clinicians and patients. To study the onset of effect of escitalopram, a selective serotonin reuptake inhibitor (SSRI), data were pooled from controlled randomized clinical double-blind trials comparing this drug with other antidepressant drugs (SSRIs and venlafaxine XR) in major depressive disorder (MDD), with assessments of the primary efficacy parameter [mean change in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score from baseline, using last observation carried forward]. The mean change in MADRS total scores was significantly higher for escitalopram-treated patients than for patients treated with the comparators on day 7 (−3.9 versus −3.4, respectively, P=0.029). This difference remained significant and in favour of escitalopram at all subsequent assessments. Using secondary outcomes (Clinical Global Impression of Improvement and Severity scales and early improvement), the results consistently showed a statistically significantly faster onset of effect of escitalopram compared to other antidepressants. In conclusion, by using the MADRS scale and pooling data from the escitalopram clinical trials in MDD comparing escitalopram with other active antidepressant drugs, escitalopram was shown to be a fast-acting antidepressant with a more rapid onset of effect than the comparators, particularly other SSRIs.

[1]  Alan Wade,et al.  Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder , 2004, International clinical psychopharmacology.

[2]  L. Colonna,et al.  A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder* , 2005, Current medical research and opinion.

[3]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care , 2002, International clinical psychopharmacology.

[4]  P. Auquier,et al.  Comparison of escitalopram and citalopram efficacy: A meta-analysis , 2003, International journal of psychiatry in clinical practice.

[5]  M. Thase,et al.  Management of treatment-resistant depression: psychotherapeutic perspectives. , 2001, The Journal of clinical psychiatry.

[6]  J. Angst,et al.  Delayed onset of action of antidepressant drugs? Survey of recent results , 1997, European Psychiatry.

[7]  Mark Zimmerman,et al.  Is there a delay in the antidepressant effect? A meta-analysis. , 2005, The Journal of clinical psychiatry.

[8]  U. Lepola,et al.  Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care , 2003, International clinical psychopharmacology.

[9]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[10]  P. Bech,et al.  Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. , 2004, The international journal of neuropsychopharmacology.

[11]  Jack M Gorman,et al.  Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials , 2002, CNS Spectrums.

[12]  J. Angst,et al.  Onset of action under antidepressant treatment , 1997, European Psychiatry.

[13]  K. Krishnan,et al.  Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy , 2005, Neuropsychopharmacology.

[14]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[15]  R. Bielski,et al.  A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. , 2004, The Journal of clinical psychiatry.

[16]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[17]  A. Nierenberg,et al.  Evidence of early onset of antidepressant effect in randomized controlled trials. , 2001, The Journal of clinical psychiatry.

[18]  H. Möller,et al.  Selecting methodologies for the evaluation of differences in time to response between antidepressants. , 2002, The Journal of clinical psychiatry.

[19]  A. Leon Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. , 2001, The Journal of clinical psychiatry.

[20]  M. Thase Methodology to measure onset of action. , 2001, The Journal of clinical psychiatry.

[21]  S. Montgomery,et al.  A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder , 2004, Neuropsychobiology.

[22]  P. Blier The pharmacology of putative early-onset antidepressant strategies , 2003, European Neuropsychopharmacology.

[23]  G. Gerhardt,et al.  New views of biogenic amine transporter function: implications for neuropsychopharmacology. , 1999, The international journal of neuropsychopharmacology.

[24]  Trevor R. Norman,et al.  Fast-Acting Antidepressants , 1994 .

[25]  J. Angst,et al.  Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo , 1994, European Psychiatry.

[26]  L. Culpepper Early onset of antidepressant action: impact on primary care. , 2001, The Journal of clinical psychiatry.

[27]  S. Kasper,et al.  Escitalopram in the treatment of depressed elderly patients. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.